Fig. 1From: A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case reportCT scans. Evaluation CT scans before start of pazopanib (a) and 12 weeks after start of pazopanib (so 6 weeks on pazopanib and 6 weeks off because of liver toxicity) (b) showing a shrinking pulmonary metastasis measured by largest diameter at both timesBack to article page